Affinage

LMO7

LIM domain only protein 7 · UniProt Q8WWI1

Length
1683 aa
Mass
192.7 kDa
Annotated
2026-06-10
37 papers in source corpus 24 papers cited in narrative 24 extracted findings
Cross-family judge faithfulness: 7/7 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

LMO7 is a multidomain scaffold and E3 ubiquitin ligase that couples cell adhesion and cytoskeletal organization to transcriptional control and protein turnover (PMID:15140894, PMID:30586711). At epithelial adherens junctions LMO7 binds afadin and alpha-actinin, bridging the nectin-afadin and E-cadherin-catenin adhesion systems (PMID:15140894), and it recruits non-muscle myosin II to apical junctions to drive actomyosin-belt formation and apical constriction during morphogenesis (PMID:35451459). This contractile function is mechanically gated: force-dependent dephosphorylation of Ser355 in the myosin-binding domain strengthens the LMO7-NMII interaction, establishing positive feedback between mechanical force and LMO7 activity (PMID:41659634). LMO7 also acts as a nucleocytoplasmic shuttling transcriptional regulator that binds emerin at the nuclear envelope and occupies myogenic promoters (Pax3, MyoD, Myf5), with emerin competing for LMO7 to form a reciprocal feedback loop governing muscle-gene expression (PMID:17067998, PMID:21525034); its cytoplasmic sequestration by p130Cas-associated focal adhesions restrains this nuclear activity (PMID:24010014). In parallel, LMO7 lowers the G/F-actin ratio to activate MRTF-SRF signaling and promote migration (PMID:21670154). As an E3 ligase, LMO7 directs K48-linked polyubiquitination and proteasomal degradation of a diverse substrate set—SMAD7, the c-FOS/c-JUN AP-1 subunits, PFKFB3, the LRP1 beta chain, MGMT, POLR2A, and SIRT3—thereby tuning TGF-beta/SMAD signaling, glycolytic macrophage activation, tumor-associated macrophage phagocytosis, drug sensitivity, and cellular senescence (PMID:30586711, PMID:38045056, PMID:40000880, PMID:41208232, PMID:41763308). Loss-of-function mouse models establish requirements in skeletal and cardiac muscle and in inner-ear cuticular-plate integrity and hearing (PMID:24825363, PMID:30850599).

Mechanistic history

Synthesis pass · year-by-year structured walk · 10 steps
  1. 2004 High

    Established LMO7 as a junctional scaffold, answering where it acts in epithelia and what adhesion systems it links.

    Evidence Reciprocal Co-IP and immunoelectron microscopy identifying afadin and alpha-actinin binding at adherens junctions

    PMID:15140894

    Open questions at the time
    • Did not define the binding domains on LMO7
    • No functional consequence of disrupting the bridge tested
  2. 2006 High

    Revealed a nuclear-envelope axis: LMO7 binds emerin and regulates emerin transcription in a feedback loop, framing LMO7 as a shuttling transcriptional regulator.

    Evidence Quantified in vitro binding (~125 nM), luciferase reporters, and siRNA knockdown with microarray in human cells

    PMID:17067998

    Open questions at the time
    • Direct DNA-binding targets of LMO7 not yet defined
    • Mechanism of nucleocytoplasmic shuttling unresolved
  3. 2011 High

    Connected LMO7's nuclear and cytoskeletal roles to muscle differentiation and actin-dependent transcription, explaining how adhesion/cytoskeletal state feeds gene programs.

    Evidence ChIP and in vitro promoter binding at Pax3/MyoD/Myf5 with emerin competition; separately reporter assays and G/F-actin fractionation linking LMO7 to MRTF-SRF

    PMID:21525034 PMID:21670154

    Open questions at the time
    • Whether actin-ratio modulation and promoter binding are mechanistically coupled is unclear
    • The Rho-independent mechanism reducing G-actin is undefined
  4. 2013 Medium

    Identified an upstream brake on LMO7 nuclear activity, showing focal-adhesion sequestration spatially regulates its transcriptional output.

    Evidence Co-IP with p130Cas and increased LMO7 nuclear activity in p130Cas-null MEFs

    PMID:24010014

    Open questions at the time
    • Direct vs indirect p130Cas binding not resolved
    • Signal that releases LMO7 to the nucleus unknown
  5. 2014 Medium

    Demonstrated physiological requirement in muscle, linking LMO7 loss to Rb and MAPK signaling defects in vivo.

    Evidence Lmo7-null mouse with histology, echocardiography, neuromuscular tests, and phospho-Western blotting

    PMID:24825363

    Open questions at the time
    • Direct molecular targets driving the muscle phenotype not identified
    • Causal link between signaling changes and tissue defects not established
  6. 2019 High

    Defined LMO7 as a negative-feedback E3 ligase in TGF-beta signaling and as a structural requirement in the inner ear, broadening its mechanistic repertoire to ubiquitination.

    Evidence SMC-specific/global knockout mice with vascular injury models plus Co-IP and ubiquitination assays for c-FOS/c-JUN; separate Lmo7 KO mouse with cochlear structural/functional assays

    PMID:30586711 PMID:30850599

    Open questions at the time
    • Which LMO7 domain confers ligase activity not yet pinned for AP-1 substrates
    • How cuticular-plate localization relates to ligase vs scaffold function unclear
  7. 2022 High

    Mechanistically resolved LMO7's contractility role by showing it recruits non-muscle myosin II to drive apical constriction in morphogenesis.

    Evidence Co-IP of NMII heavy chain, morpholino knockdown, and overexpression in Xenopus ectoderm with neural-tube phenotype

    PMID:35451459

    Open questions at the time
    • Regulation of the NMII interaction in mammalian tissue not tested
    • Relationship to junctional adhesion partners not integrated
  8. 2023 Medium

    Extended the E3-ligase function to metabolism and immunity, showing LMO7 degrades PFKFB3 to restrain glycolytic macrophage activation.

    Evidence K48-linkage ubiquitination assay, Co-IP, knockdown, and murine colitis model

    PMID:38045056

    Open questions at the time
    • Recognition determinants on PFKFB3 not mapped
    • How LMO7 selects this substrate over others unknown
  9. 2025 High

    Identified site-specific substrate ubiquitination as a recurring mechanism, with SMAD7 (K70) degradation stabilizing TGFbetaR1 to promote fibrosis.

    Evidence Co-IP, site-specific K70 ubiquitination mutagenesis, KO fibroblasts, and bleomycin fibrosis model with AAV-shRNA

    PMID:40000880

    Open questions at the time
    • Reconciliation with LMO7's opposite (negative-feedback) role in vascular TGF-beta signaling not addressed
    • Context determinants of pro- vs anti-fibrotic output unresolved
  10. 2026 Medium

    Consolidated LMO7 as a multi-substrate E3 ligase via site-specific K48 ubiquitination, linking it to phagocytosis, senescence, drug sensitivity, and osteoarthritis.

    Evidence Site-specific ubiquitination mutagenesis and Co-IP for LRP1 (K45), POLR2A, MGMT (F-box-dependent), and SIRT3 across KO/knockdown models and disease systems

    PMID:41208232 PMID:41763308 PMID:41896199 PMID:41992271

    Open questions at the time
    • A unifying substrate-recognition logic across these targets is undefined
    • Whether the F-box domain mediates all substrates or only MGMT is unclear

Open questions

Synthesis pass · forward-looking unresolved questions
  • How a single scaffold reconciles its opposing context-dependent roles (e.g. negative vs positive regulation of TGF-beta; scaffold vs ligase activity) through domain usage, post-translational control, and substrate selection remains unresolved.
  • No structural model relating LIM/PDZ/F-box domains to substrate choice
  • Switch between adhesion-scaffold and E3-ligase modes uncharacterized
  • Determinants of tissue-specific substrate repertoire unknown

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140096 catalytic activity, acting on a protein 7 GO:0016874 ligase activity 5 GO:0008092 cytoskeletal protein binding 4 GO:0140110 transcription regulator activity 3 GO:0060090 molecular adaptor activity 2
Localization
GO:0005634 nucleus 2 GO:0005856 cytoskeleton 2 GO:0005886 plasma membrane 2 GO:0005829 cytosol 1
Pathway
R-HSA-392499 Metabolism of proteins 4 R-HSA-1266738 Developmental Biology 3 R-HSA-74160 Gene expression (Transcription) 3 R-HSA-162582 Signal Transduction 2 R-HSA-168256 Immune System 2
Partners
ACTNAFDNEMDMGMTMYH9P130CASPOLR2ASMAD7

Evidence

Reading pass · 24 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2006 LMO7 binds directly to emerin with ~125 nM affinity; the C-terminal half of human LMO7 is sufficient for this interaction in vitro. LMO7 is a nucleocytoplasmic shuttling protein that positively regulates emerin gene transcription (emerin mRNA decreased 93% on LMO7 knockdown), and emerin binding to LMO7 inhibits LMO7 transcriptional activity in a feedback loop. In vitro binding assay (affinity measurement), luciferase reporter assay, siRNA knockdown, microarray, real-time PCR Human molecular genetics High 17067998
2004 LMO7 is an afadin- and alpha-actinin-binding protein at adherens junctions. It connects the nectin-afadin cell-cell adhesion system to the E-cadherin-catenin system through alpha-actinin, and localizes at cell-cell adherens junctions and apical membranes in epithelial cells. Immunoprecipitation, immunofluorescence, immunoelectron microscopy, Western blotting The Journal of biological chemistry High 15140894
2011 LMO7 binds the Pax3, MyoD, and Myf5 promoters in C2C12 myoblasts and in vitro, and is required for myoblast differentiation. Emerin competes with these promoters for LMO7 binding, inhibiting LMO7-driven transcriptional activation of MyoD and Pax3 promoters. ChIP, in vitro promoter-binding assay, siRNA knockdown, overexpression, Co-IP competition assay Journal of cell science High 21525034
2011 LMO7 activates myocardin-related transcription factors (MRTFs) by relieving actin-mediated inhibition in a manner synergistic with Rho GTPase. LMO7 colocalizes with F-actin and reduces the G-actin/F-actin ratio via a Rho-independent mechanism, promoting MRTF-SRF signaling and breast cancer cell migration. Reporter assay, siRNA knockdown, G/F-actin fractionation, cell migration assay, colocalization imaging Molecular and cellular biology High 21670154
2013 Endogenous LMO7 associates with focal adhesions, co-localizing and co-immunoprecipitating with p130Cas. LMO7 nuclear localization and transcriptional activity increased in p130Cas-null MEFs, indicating that p130Cas-dependent focal adhesion association negatively regulates LMO7 nuclear activity. Co-immunoprecipitation, immunofluorescence, genetic knockout (p130Cas-null MEFs), transcriptional reporter assay PeerJ Medium 24010014
2014 Lmo7-null mice display growth retardation, decreased muscle fiber size, and impaired skeletal and cardiac function with lower levels of phosphorylated Rb, ERK, and JNK, consistent with altered Rb and MAPK signaling pathways. Lmo7-null mouse generation, histological analysis, echocardiography, neuromuscular tests, Western blotting Muscle & nerve Medium 24825363
2019 LMO7 is induced by TGF-β in vascular smooth muscle cells and acts as a negative feedback regulator of TGF-β signaling. Mechanistically, the LMO7 LIM domain interacts with AP-1 subunits c-FOS and c-JUN and promotes their ubiquitination and degradation, disrupting AP-1-dependent TGF-β autoinduction. LMO7 deletion amplifies TGF-β signaling, ECM deposition, and neointimal formation. SMC-specific and global LMO7 knockout mice, carotid ligation/femoral artery denudation models, knockdown, overexpression, mutagenesis, Co-IP, Western blotting for ubiquitination Circulation High 30586711
2019 LMO7 is specifically localized in the cuticular plate and cell junctions of inner ear hair cells. Lmo7 KO mice develop cuticular plate deficiencies (reduced F-actin density, abnormal stereociliar rootlets) and late-onset progressive hearing loss, demonstrating LMO7 is required for cuticular plate integrity and cochlear mechanotransduction. Lmo7 KO mouse, immunofluorescence/localization, auditory brainstem response, cochlear mechanics, electron microscopy Nature communications High 30850599
2021 The Cryptosporidium rhoptry effector protein ROP1 directly interacts with LMO7 in the host cell terminal web. LMO7 acts as an organizer of epithelial cell polarity and cell-cell adhesion, and genetic ablation of LMO7 in mice impacts parasite burden in vivo. Parasite effector screen, direct interaction assay, genetic ablation (LMO7 KO mice), in vivo infection model Cell host & microbe Medium 34348092
2022 LMO7 binds non-muscle myosin II (NMII) heavy chain and recruits it to apical junctions and the apical cortex in Xenopus ectoderm. This NMII recruitment is essential for LMO7-mediated apical constriction and promotion of circumferential actomyosin belt formation. LMO7 knockdown decreases NMIIA localization at apical junctions and delays neural tube closure. Co-immunoprecipitation, immunofluorescence, morpholino knockdown, overexpression in Xenopus embryos Development (Cambridge, England) High 35451459
2023 LMO7 directly degrades PFKFB3 (a glycolysis regulator) through K48-linked polyubiquitination in macrophages. LMO7-mediated PFKFB3 degradation inhibits glycolysis and macrophage activation; PFKFB3 also regulates histone demethylase JMJD3 expression, thereby modulating H3K27me3 levels. This LMO7/PFKFB3/JMJD3 axis modulates macrophage function and inflammatory bowel disease. Ubiquitination assay (K48-linkage), Co-IP, siRNA knockdown, Western blotting, murine colitis model Acta pharmaceutica Sinica. B Medium 38045056
2025 LMO7 acts as an E3 ubiquitin ligase that binds SMAD7, mediating its polyubiquitination at lysine 70 and proteasomal degradation, thereby increasing the stability of TGF-β receptor 1 (TGFβR1) and promoting profibrotic fibroblast polarization and pulmonary fibrosis. Co-IP, ubiquitination assay (site-specific K70 mutation), Western blotting, KO fibroblasts, BLM-induced fibrosis mouse model, AAV-mediated shRNA Acta pharmacologica Sinica High 40000880
2025 LMO7 inhibits tumor-associated macrophage (TAM) phagocytosis by promoting K48-linked polyubiquitination at lysine 45 of the β chain of LRP1, leading to its proteasomal degradation. LMO7 deficiency enhances TAM phagocytic activity and antitumor immune responses. Ubiquitination assay (K48-linkage, K45 mutation), Co-IP, single-cell RNA-seq, LMO7 KO mouse tumor models, Western blotting Advanced science High 41208232
2026 LMO7 acts as an E3 ubiquitin ligase that is recruited to POLR2A (the largest subunit of RNA polymerase II), promoting its ubiquitination and proteasomal degradation. LMO7-mediated POLR2A degradation drives cellular senescence through the MDM4/p53/p21 axis. Depletion of LMO7 abolished POLR2A ubiquitination and reduction in H2O2-induced senescent cells. Co-immunoprecipitation, ubiquitination assay, siRNA knockdown, Western blotting, CRISPRa Cell death & disease Medium 41896199
2026 LMO7 directly binds MGMT via its F-box domain and promotes K48-linked polyubiquitination and proteasomal degradation of MGMT, increasing temozolomide sensitivity in NSCLC cells. TMZ treatment further strengthens the LMO7-MGMT interaction, creating a positive feedback loop accelerating MGMT degradation. Co-IP, ubiquitination assay (K48-linkage), F-box domain mutagenesis, MGMT-C145A catalytic mutant, cell viability assay The Journal of biological chemistry High 41763308
2018 A recurrent LMO7-BRAF fusion protein was identified in papillary thyroid carcinoma; enforced expression of LMO7-BRAF stimulated endogenous ERK1/2 phosphorylation and promoted anchorage-independent cell growth, demonstrating oncogenic activity of the fusion. RT-PCR, FISH, Sanger sequencing, enforced expression, ERK1/2 phosphorylation assay, anchorage-independent growth assay Thyroid Medium 29768105
2017 LMO7 interacts with the spindle assembly checkpoint (SAC) protein MAD1. Overexpression but not depletion of LMO7 caused a SAC defect; the LIM domain of LMO7 interfered with kinetochore localization of MAD2 and BUBR1 but not MAD1. Overexpression of the LIM peptide prolonged mitotic timing and interfered with chromosome congression. Co-immunoprecipitation, immunofluorescence, overexpression and knockdown experiments, live-cell imaging of mitosis The international journal of biochemistry & cell biology Medium 29158164
2016 LMO7 knockdown in chick primary skeletal muscle cells reduces myotube number and width and reduces MyoD-positive myoblasts. Activation of Wnt/beta-catenin pathway (Wnt3a or Bio treatment) rescues the LMO7 knockdown phenotype, indicating crosstalk between Wnt/beta-catenin and LMO7-mediated signaling in myogenesis. siRNA knockdown, immunofluorescence, pharmacological rescue (Wnt3a, Bio) FEBS letters Medium 26786059
2022 LMO7 is a positive regulator of fibroblast polarization and intrinsic directed migration (IDM). LMO7 is predominantly incorporated into the cytoskeletons of normal fibroblasts, and its depletion inhibits directed migration on fibronectin-rich surfaces and impairs morphological polarity establishment. Cytoskeletal fractionation proteomics, siRNA knockdown, live-cell migration assay, fibronectin-coated surfaces Biochemical and biophysical research communications Medium 36442233
2022 LMO7 coordinates with FAK signaling to maintain epithelial junctional integrity under osmotic stress in renal epithelial cells. LMO7 depletion causes junctional integrity loss; FAK inhibition prevents robust cortical F-actin assembly and LMO7 association with cortical F-actin. LMO7-depleted cells show excessive FAK activation, suggesting LMO7 regulates FAK activation. siRNA depletion, FAK inhibitor (PF-573228), immunofluorescence, TEER/junctional integrity assay, hypertonic stress model Cells Medium 36497072
2025 VILL (villin-like protein) directly interacts with LMO7 (E3 ubiquitin ligase) in the cytoplasm of nasopharyngeal carcinoma cells, as determined by Co-IP and GST pull-down. Overexpression of LMO7 partially counteracted the inhibitory effect of VILL on NPC cell proliferation. Co-immunoprecipitation, mass spectrometry, GST pull-down, Western blotting, immunofluorescence, overexpression rescue Nan fang yi ke da xue xue bao Medium 40415426
2026 LMO7 ubiquitinates SIRT3, leading to its degradation and subsequent osteoarthritis progression. Molecular experiments confirmed the ability of LMO7 to ubiquitinate SIRT3 in vitro and in vivo. Ubiquitination assay, Co-IP, in vitro and in vivo experiments, molecular docking BMC biology Medium 41992271
2026 Force-dependent dephosphorylation of Ser355 in the LMO7 myosin-binding domain enhances LMO7 binding to non-muscle myosin II (NMII) and increases NMII abundance at the apical cortex during neural tube closure in Xenopus. LMO7 is required to stabilize actomyosin at the apical cortex at the onset of neural tube folding, suggesting a positive feedback between mechanical forces and LMO7 activity. Morpholino knockdown, gain-of-function injection, phospho-specific mutants (Ser355), Co-IP, live imaging in Xenopus embryos bioRxivpreprint Medium 41659634
2005 TGF-β1 upregulates LMO7 and a splice variant LMO7S (PDZ domain only) in rat ascites hepatoma cells; LMO7 expression is elevated in highly metastatic clones, and TGF-β1-induced LMO7 upregulation is associated with enhanced invasive capacity. Differential hybridization, RT-PCR, invasion assay Cancer letters Low 15737692

Source papers

Stage 0 corpus · 37 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2016 Circulating exosomal microRNA-96 promotes cell proliferation, migration and drug resistance by targeting LMO7. Journal of cellular and molecular medicine 140 28026121
2006 Lmo7 is an emerin-binding protein that regulates the transcription of emerin and many other muscle-relevant genes. Human molecular genetics 140 17067998
2004 Involvement of LMO7 in the association of two cell-cell adhesion molecules, nectin and E-cadherin, through afadin and alpha-actinin in epithelial cells. The Journal of biological chemistry 127 15140894
2019 LMO7 Is a Negative Feedback Regulator of Transforming Growth Factor β Signaling and Fibrosis. Circulation 76 30586711
2003 An engineered 800 kilobase deletion of Uchl3 and Lmo7 on mouse chromosome 14 causes defects in viability, postnatal growth and degeneration of muscle and retina. Human molecular genetics 62 12761045
2011 LMO7 mediates cell-specific activation of the Rho-myocardin-related transcription factor-serum response factor pathway and plays an important role in breast cancer cell migration. Molecular and cellular biology 61 21670154
2011 Emerin inhibits Lmo7 binding to the Pax3 and MyoD promoters and expression of myoblast proliferation genes. Journal of cell science 60 21525034
2021 Cryptosporidium rhoptry effector protein ROP1 injected during invasion targets the host cytoskeletal modulator LMO7. Cell host & microbe 55 34348092
2019 LMO7 deficiency reveals the significance of the cuticular plate for hearing function. Nature communications 39 30850599
2005 Differential expression and molecular characterisation of Lmo7, Myo1e, Sash1, and Mcoln2 genes in Btk-defective B-cells. Cellular immunology 36 16137664
2011 Decreased expression of LMO7 and its clinicopathological significance in human lung adenocarcinoma. Experimental and therapeutic medicine 26 22977619
2021 LMO7 as an Unrecognized Factor Promoting Pancreatic Cancer Progression and Metastasis. Frontiers in cell and developmental biology 25 33763427
2018 Identification of a Recurrent LMO7-BRAF Fusion in Papillary Thyroid Carcinoma. Thyroid : official journal of the American Thyroid Association 24 29768105
2023 Macrophage LMO7 deficiency facilitates inflammatory injury via metabolic-epigenetic reprogramming. Acta pharmaceutica Sinica. B 23 38045056
2005 Transforming growth factor-beta1 induces LMO7 while enhancing the invasiveness of rat ascites hepatoma cells. Cancer letters 23 15737692
2014 LMO7-null mice exhibit phenotypes consistent with emery-dreifuss muscular dystrophy. Muscle & nerve 20 24825363
2013 The emerin-binding transcription factor Lmo7 is regulated by association with p130Cas at focal adhesions. PeerJ 20 24010014
2021 A Novel Circular RNA circITSN2 Targets the miR-218-5p/LMO7 Axis to Promote Chicken Embryonic Myoblast Proliferation and Differentiation. Frontiers in cell and developmental biology 17 34692701
2022 Lmo7 recruits myosin II heavy chain to regulate actomyosin contractility and apical domain size in Xenopus ectoderm. Development (Cambridge, England) 15 35451459
2024 Exosome-transmitted circular RNA circ-LMO7 facilitates the progression of osteosarcoma by regulating miR-21-5p/ARHGAP24 axis. Cancer biology & therapy 14 38742566
2016 Knockdown of Lmo7 inhibits chick myogenesis. FEBS letters 14 26786059
2015 Lmo7 is dispensable for skeletal muscle and cardiac function. American journal of physiology. Cell physiology 13 26157009
2021 New Findings on LMO7 Transcripts, Proteins and Regulatory Regions in Human and Vertebrate Model Organisms and the Intracellular Distribution in Skeletal Muscle Cells. International journal of molecular sciences 9 34884689
2017 LMO7 exerts an effect on mitosis progression and the spindle assembly checkpoint. The international journal of biochemistry & cell biology 8 29158164
2021 BMSCs attenuate hepatic fibrosis in autoimmune hepatitis through regulation of LMO7-AP1-TGFβ signaling pathway. European review for medical and pharmacological sciences 7 33629329
2025 LMO7 drives profibrotic fibroblast polarization and pulmonary fibrosis in mice through TGF-β signalling. Acta pharmacologica Sinica 6 40000880
2022 Coordination of LMO7 with FAK Signaling Sustains Epithelial Integrity in Renal Epithelia Exposed to Osmotic Pressure. Cells 4 36497072
2022 LMO7-ALK Fusion in a Lung Adenocarcinoma Patient With Crizotinib: A Case Report. Frontiers in oncology 3 35664754
2023 Novel Long Non-Coding RNA (lncRNA) Transcript AL137782.1 Promotes the Migration of Normal Lung Epithelial Cells through Positively Regulating LMO7. International journal of molecular sciences 2 37762205
2026 Force-dependent stabilization of apical actomyosin by Lmo7 during vertebrate neurulation. bioRxiv : the preprint server for biology 0 41659634
2026 E3 ligase LMO7 enhances temozolomide sensitivity by promoting MGMT degradation in lung cancer. The Journal of biological chemistry 0 41763308
2026 LMO7-mediated POLR2A degradation promotes cellular senescence through the MDM4/p53/p21 axis. Cell death & disease 0 41896199
2026 LMO7-mediated ubiquitination of SIRT3 promotes osteoarthritis progression: an investigation using machine learning and molecular dynamics simulations. BMC biology 0 41992271
2025 Comprehensive analysis of ESCRT transcriptome-associated signatures and identification of the regulatory role of LMO7-AS1 in osteosarcoma. Cancer cell international 0 39885569
2025 [Villin-like protein VILL suppresses proliferation of nasopharyngeal carcinoma cells by interacting with LMO7 protein]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University 0 40415426
2025 LMO7 Suppresses Tumor-Associated Macrophage Phagocytosis of Tumor Cells Through Degradation of LRP1. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 0 41208232
2022 Cytoskeletal fractionation identifies LMO7 as a positive regulator of fibroblast polarization and directed migration. Biochemical and biophysical research communications 0 36442233

Missed literature

Know a paper Affinage missed for LMO7? Flag it for the maintainers and the community.

No submissions yet.